

The Effect of Carbetocin versus Misoprostol versus Ergometrine for Controlling Bleeding after Cesarean Section in Primigravidae

Abstract

Background: Women undergoing cesarean section have a high risk of blood loss and so are more likely to need a blood transfusion. The aim of this work was to compare the effectiveness of using carbetocin versus misoprostol versus ergometrine for controlling bleeding after cesarean section in primigravidae.

Methods: This prospective randomized clinical trial was conducted on 150 patients aged from 18-35 years old, primigravidae with singleton pregnancy undergoing elective cesarean section. Participants were divided into three equal groups: carbetocin group (group C) received a single 1-ml ampoule of carbetocin (100 µg/mL) added to 10 cm saline intravenously following the delivery of the neonate, misoprostol group (group M) received misoprostol 400ug per rectum immediately after induction of anesthesia in operating theater and ergometrine group (group E) received 0.2 mg of ergometrine intramuscularly in the first minute after delivery of the baby.

Results: The amount of blood in suction jar, amount of blood loss, Hb change and HTC change were significantly higher in the misoprostol group and ergometrine group than in the carbetocin group ($p < 0.05$) and in the ergometrine group than the misoprostol group ($p < 0.001$). Post-operative Hb in the ergometrine group was significantly lower in the carbetocin group ($p = 0.001$).

Conclusions: Carbetocin can be considered a superior choice to misoprostol and ergometrine in reducing blood loss during CS in primigravidae.

Keywords: Carbetocin, Misoprostol, Ergometrine, Cesarean Section, Primigravidae

UNDER PEER REVIEW

Introduction:

“Cesarean delivery is one of the most frequently performed major surgical procedures worldwide”^[1]. “Compared with women who deliver vaginally, women undergoing cesarean section have a high risk of blood loss and so are more likely to need a blood transfusion”^[2].

“The global increase in the incidence of cesarean delivery in the past decade has contributed to the appearance of postpartum hemorrhage (PPH)”^[3]. “The risk of postpartum hemorrhage is further increasing in the presence of risk factors such as multiparity, polyhydramnios, grand multiparity, severe pre-eclampsia, antepartum hemorrhage, prolonged and obstructed labor, augmented labor, obesity, and anemia”^[4].

“The currently accepted definition is to consider post-partum hemorrhage as blood loss of more than 500 mL regardless the type of delivery and severity as blood loss more than 1000 mL”^[5]. “The American College of Obstetricians and Gynecologists considered that a decline in hematocrit of a rate of 10% or more constituted post-partum hemorrhage”^[6].

“The aim of the treatment of postpartum hemorrhage is to restore myometrium contraction. For that, the following therapeutic options are used, alone or in combination: stimulation of uterine contractility with manual massage of the uterus; administration of oxytocin, misoprostol, ergometrine. Note also that the increased sensitivity of the gravid uterus to these drugs contributes to their therapeutic efficiency”^[7].

Accordingly, “the administration of uterotonic agents during cesarean section (CS) and vaginal delivery has become crucial to diminish the risk of post-partum hemorrhage and improve maternal safety”^[8].

“Oxytocin is considered as the gold standard uterotonic drug but has a short half-life of 4–10 min; hence, at cesarean section oxytocin must be ordered as a continuous intravenous infusion to achieve continuous uterotonic activity during the surgical procedure and the direct

postpartum period. Misoprostol is a prostaglandin E1 analog supported in several randomized controlled trials to be efficient in preventing PPH because of its strong uterotonic effect”^[8].

In addition, “misoprostol is low-cost, stable at room temperature, and easily administered. misoprostol has been widely studied in the prevention and treatment of post-partum hemorrhage after vaginal delivery; however, its usage in conjunction with cesarean section has not been studied as much”^[9]. “The sublingual route is known as having the greatest benefit due to its rapid uptake, long-acting effect, and great bioavailability compared with other routes of intake”^[10].

“Carbetocin, a long-acting oxytocin analogue, has been described to decrease the requirement for additional uterotonics during cesarean section in comparison with oxytocin. A 100- μ g dose of carbetocin has been recommended for preventing Post-partum hemorrhage. Carbetocin has been recommended for post-partum hemorrhage prevention after elective cesarean deliveries. Advantages of carbetocin over oxytocin is that owed to its long action and half-life, it is administrated as a single intravenous dose, while oxytocin necessitates frequent administration or continuous infusion over several hours, with differences in doses”^[11].

“In comparison to Oxytocin, the administration of Ergometrine results in a sustained tonic uterine contraction through stimulation of myometrial α -adrenergic receptors. Both uterine segments are thus stimulated to contract in a tetanic way. Intramuscular injection of the usual 0.25 mg dose effects in an onset of action of 2–5 minutes”^[12].

The aim of this work was to compare the effectiveness of using carbetocin versus misoprostol versus ergometrine for controlling bleeding after cesarean section in primigravidae.

Patients and Methods:

This prospective randomized clinical trial was conducted on 150 patients aged from 18-35 years old, BMI (18.5 – 29.9) primigravidae with singleton pregnancy undergoing elective

cesarean section at The Department of obstetrics and gynecology, Tanta university hospitals, Egypt 1st of February 2020 to 31st of January 2021.

Exclusion criteria were hypersensitivity to Ergometrine, Carbetocin, prostaglandins or contraindication to treatment with prostaglandins (e.g., glaucoma), history of significant heart disease, severe asthma. Epilepsy, history or evidence of liver, renal, or vascular disease; history of coagulopathy, thrombocytopenia, or anticoagulant therapy; HELLP syndrome or eclampsia; placental abruption; or contraindication to spinal anesthesia and PPH due to causes other than uterine atony.

All patients were subjected to: history taking, clinical examination, investigational studies such as pelvi-abdominal ultrasound and preoperative and postoperative hemoglobin.

Eligible and consenting participants were randomized via a computer-generated random number sequence into one of three groups of 50 each.

The carbetocin group (group C) received a single 1-ml ampoule of carbetocin (100 µg/mL) added to 10 cm saline that was administered intravenously following the delivery of the fetus.

The misoprostol group (group M) received misoprostol 400ug per rectum immediately after induction of anesthesia in the operating theater.

The ergometrine group (group E) received 0.2 mg of ergometrine intramuscularly in the first minute after delivery of the baby.

The primary outcomes were the measured intraoperative and postoperative (end of cesarean delivery to 8 hours postpartum) blood loss. The secondary outcomes were postoperative change in hemoglobin (24 hours after delivery), need for additional oxytocics (over 24 hours), and drug-related side effects. The volume of blood in the suction bottle and blood-soaked sponges was measured. Hemoglobin values were determined both before surgery and 24 h following surgery. The need for additional oxytocic therapy, need for blood transfusion

(until discharge), and side effects of study drugs, cost of the drugs used, and any significant puerperal morbidity were also recorded.

Statistical analysis

Statistical analysis was done by SPSS v26 (IBM Inc., Chicago, IL, USA). Quantitative variables were presented as mean and standard deviation (SD) and compared between the two groups utilizing ANOVA (F) test. Qualitative variables were presented as frequency and percentage (%) and were analysed utilizing the Chi-square test. A two tailed P value < 0.05 was considered statistically significant.

Results:

As regard of socio-demographic data (age and BMI), gestational age and indications of CS (infertility, abnormal Presentation, low-lying placenta, abnormal Liquor, fetal macrosomia and CPD), there was no statistically significant difference between the three groups. Table 1

Table 1: Comparison between study groups as regard of socio-demographic data, Gestational age and indications of CS

	Carbetocin group (n= 50)	Misoprostol group (n= 50)	Ergometrine group (n= 50)	P value
Age (years)	27.38 ± 4.827	27.58 ± 4.380	26.38 ± 4.237	0.361
BMI (kg/m²)	26.43 ± 2.067	26.31 ± 2.778	26.20 ± 2.408	0.896
Gestational age (weeks)	36.80 ± 1.578	37.22 ± 1.447	36.88 ± 1.599	0.354
Infertility	0.0% (0)	10.0% (5)	8.0% (4)	0.268
Abnormal Presentation	66.0% (33)	58.0% (29)	70.0% (35)	
Low-lying placenta	14.0% (7)	24.0% (12)	12.0% (6)	
Abnormal Liquor	10.0% (5)	4.0% (2)	4.0% (2)	
Fetal macrosomia	6.0% (3)	2.0% (1)	4.0% (2)	
CPD	4.0% (2)	2.0% (1)	2.0% (1)	

Data are presented as mean ± SD or percentage (frequency). CPD: Cephalopelvic disproportion.

The amount of blood in suction jar, amount of blood loss, Hb change and HTC change was statistically significantly higher in the misoprostol group and ergometrine group than in the carbetocin group ($p < 0.05$) and was statistically significantly higher in the ergometrine group than the misoprostol group ($p < 0.001$). Post-operative Hb in the ergometrine group was statistically significantly lower in the carbetocin group ($p_2 = 0.001$). Operative duration, basal Hb, basal Hct, post-operative Hct, need for transfusion, need for additional oxytocic, hospital stay were insignificantly different among the studied groups. Post-operative Hb was insignificantly different between carbetocin and misoprostol groups. Table 2

Table 2: Duration of surgery, amount of blood loss, basal and post-operative hemoglobin and hematocrit values, need for blood transfusion, additional oxytocic and total hospital stay in studied groups

	Carbetocin group (n= 50)	Misoprostol group (n= 50)	Ergometrine group (n= 50)	P	P1	P2	P3
Operative duration (minutes)	46.10 ± 7.7 12	48.70 ± 9.357	48.90 ± 7.712	0.174	0.358	0.281	1
Blood in suction jar (ml)	273.50 ± 44 .150	327.50 ± 54.6 91	413.50 ± 54.2 13	< 0.00 1*	< 0.001 *	< 0.001 *	< 0.0 01*
Estimated blood loss (ml)	694.00 ± 70 .992	749.00 ± 54.8 56	875.00 ± 75.9 30	< 0.00 1*	< 0.001 *	< 0.001 *	< 0.0 01*
Basal Hb (gm/dl)	11.43 ± 0.8 23	11.33 ± 0.781	11.32 ± 0.712	0.718	1	1	1
Post-operative Hb (gm/dl)	10.05 ± 0.7 66	9.83 ± 0.677	9.55 ± 0.633	0.002*	0.336	0.001*	0.132
Hb change (gm)	- 1.38 ± 0.20	-1.50 ± 0.220	-1.78 ± 0.257	< 0.00 1*	0.037*	< 0.001 *	< 0.0 01*

	7						
Basal Hct (%)	39.13 ± 39.164	33.43 ± 2.030	33.44 ± 1.799	0.352	0.632	0.634	1
Post-operative Hct (%)	31.29 ± 1.819	30.96 ± 1.942	30.57 ± 1.667	0.145	1	0.150	0.874
Hct change (%)	-2.26 ± 0.313	-2.48 ± 0.299	-2.87 ± 0.376	< 0.001*	0.005*	< 0.001*	< 0.001*
Need for transfusion	6.0% (3)	6.0% (3)	8.0% (4)	0.898	> 0.05	> 0.05	> 0.05
Need for additional oxytocic	12.0% (6)	22.0% (11)	28.0% (14)	0.136	> 0.05	> 0.05	> 0.05
Hospital stay (hours)	30.96 ± 8.430	29.52 ± 11.165	27.84 ± 10.124	0.296	1	0.359	1

Data are presented as mean ± SD or percentage (frequency), * is significant when < 0.05. P1: Carbetocin group & Misoprostol group. P2: Carbetocin group & Ergometrine group. P3: Misoprostol group & Ergometrine group. Hb: Haemoglobin, Hct: Hematocrit.

Discussion

In this study, there was no statistically significant difference between the three studied groups as regards the operation duration. This was comparable with a study conducted by Owonikoko et al.^[13] who reported the insignificance of the operation time when they studied the effect of sublingual misoprostol versus intravenous oxytocin on reducing blood loss at CS in Nigeria.

In the current study, the amount of blood in a suction jar and the estimated blood loss were statistically significantly lower in the carbetocin group than the other two groups. The post-operative Hb in the ergometrine group was statistically significantly lower in the carbetocin group than the other two groups. Hb change and Hct change were statistically significantly lower in the carbetocin group than the other two groups.

The need for transfusion and the need for additional oxytocic were significantly lower in the carbetocin group. However, the hospital stay was higher in the carbetocin group than in the two other groups.

Many studies worldwide compared misoprostol to oxytocin ^[14, 15] and carbetocin to oxytocin ^[11, 16] in reducing blood loss during cesarean section. However, few studies compared carbetocin to misoprostol in reducing blood loss during cesarean section.^[17]

We found that carbetocin is superior to ergotamine in reducing blood loss in CS in primigravida. In the same line with our results, Su et al. ^[18, 19] in the cochrane of 2007 regarding “oxytocin agonists for preventing postpartum hemorrhage” ^[18], and in the cochrane 2012 regarding “carbetocin for preventing postpartum hemorrhage” ^[19], conclude that the use of carbetocin is more effective than oxytocin for preventing PPH in women undergoing cesarean section, but the data and the evidence were still insufficient.

We found that misoprostol is superior to ergotamine in reducing blood loss in CS in primigravida. In agreement with our results, Gupta et al. ^[20] found that misoprostol is effective as intramuscular oxytocin in reducing blood loss during cesarean section, however, it has more side effects as regarding transient pyrexia and shivering. Also, Adanikin Al et al. ^[21] who compared oxytocin infusion to 600ug rectal misoprostol after cesarean section in tropical climates where there is a little capability for refrigeration, found that Misoprostol is as effective as oxytocin infusion for the prevention of PPH.

On the contrary, Elbohoty et al.^[22] reported that oxytocin was more effective than misoprostol in reducing blood loss during cesarean delivery and in reducing the need for postoperative uterotonics; additionally, adverse effects were found to be more common with misoprostol than with oxytocin.

Additionally, some studies have demonstrated misoprostol 400–600- μ g to be as effective as oxytocin ^[14, 15], and a combination of misoprostol 200 μ g with oxytocin has been demonstrated to reduce blood loss and the need for additional uterotonics ^[23].

We found that carbetocin is superior to misoprostol in reducing blood loss in CS in primigravida. In agreement with our study, Moustafa et al.^[17] concluded that intravenous therapy infusion of 100 μ g carbetocin is more effective in managing blood loss during CS than 600 μ g rectal misoprostol.

A previous Egyptian study that enrolled 380 patients compared a combination of sublingual misoprostol and oxytocin infusion with intravenous carbetocin in the prevention of PPH during cesarean delivery in high-risk patients. the authors concluded that combined misoprostol–oxytocin was as effective as intravenous carbetocin in reducing the need for additional uterotonics ^[24].

A systematic review ^[19] of 11 studies included four studies that compared carbetocin (100 μ g administered intravenously) with oxytocin in patients undergoing cesarean delivery. In comparison with oxytocin, carbetocin demonstrated a statistically significant reduction in the use of additional uterotonics. However, no statistically significant difference was reported between carbetocin and oxytocin in terms of the risk of patients experiencing PPH (500–1000-mL blood loss) or severe PPH (>1000-mL blood loss).

In the present study, the need for blood transfusion was significantly lower in the carbetocin group. This was in agreement with Ali et al.^[25] and Moustafa et al.^[17] who found that carbetocin decreases the need for blood transfusion after cesarean.

Overall, our data suggested the superiority of carbetocin over misoprostol in preventing PPH during CS in primigravidae.

Conclusions:

Carbetocin was demonstrated to be superior to misoprostol in preventing PPH evident by a lower amount of blood in a suction jar and lower estimated blood loss as well as lower Hb and hematocrit deficit pre- and post-operatively. Consequently, it is suggested that carbetocin can be considered a superior choice to misoprostol and ergometrine in reducing blood loss during CS in primigravidae.

Ethical approval and Consent:

The study was done after being approved by the Ethical Committee, Tanta University Hospitals. An informed written consent was obtained from all included subjects.

References:

1. Betrán AP, Merialdi M, Lauer JA, Bing-Shun W, Thomas J, Van Look P, et al. Rates of caesarean section: analysis of global, regional and national estimates. *Paediatr Perinat Epidemiol.* 2007;21:98-113.
2. Magann EF, Evans S, Hutchinson M, Collins R, Lanneau G, Morrison JC. Postpartum hemorrhage after cesarean delivery: an analysis of risk factors. *South Med J.* 2005;98:681-5.
3. Borovac-Pinheiro A, Priyadarshani P, Burke TF. A review of postpartum hemorrhage in low-income countries and implications for strengthening health systems. *Int J Gynaecol Obstet.* 2021;154:393-9.
4. Ngwenya S. Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting. *Int J Womens Health.* 2016;8:647-51.
5. Sentilhes L, Vayssière C, Mercier FJ, Aya AG, Bayoumeu F, Bonnet MP, et al. [Postpartum hemorrhage: Guidelines for clinical practice - Text of the Guidelines (short text)]. *J Gynecol Obstet Biol Reprod (Paris).* 2014;43:1170-9.
6. Jones R. Quantitative measurement of blood loss during delivery. *Obstet Gynecol Neonatal Nurs.* 2015;44:41-5.

7. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage: World Health Organization; 2012.
8. Chong YS, Su LL, Arulkumaran S. Current strategies for the prevention of postpartum haemorrhage in the third stage of labour. *Curr Opin Obstet Gynecol*. 2004;16:143-50.
9. Nasr A, Shahin AY, Elsamman AM, Zakherah MS, Shaaban OM. Rectal misoprostol versus intravenous oxytocin for prevention of postpartum hemorrhage. *Int J Gynaecol Obstet*. 2009;105:244-7.
10. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. *Int J Gynaecol Obstet*. 2007;99:160-7.
11. Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani B, et al. Carbetocin versus oxytocin in caesarean section with high risk of post-partum haemorrhage. *J Perinat Med*. 2013;7:12-8.
12. Fanning RA, Sheehan F, Leyden C, Duffy N, Iglesias-Martinez LF, Carey MF, et al. A Role for Adrenergic Receptors in the Uterotonic Effects of Ergometrine in Isolated Human Term Nonlaboring Myometrium. *Anesth Analg*. 2017;124:1581-8.
13. Owonikoko KM, Arowojolu AO, Okunlola MA. Effect of sublingual misoprostol versus intravenous oxytocin on reducing blood loss at cesarean section in Nigeria: A randomized controlled trial. *J Obstet Gynaecol Res*. 2011;37:715-21.
14. Lapaire O, Schneider MC, Stotz M, Surbek DV, Holzgreve W, Hoesli IM. Oral misoprostol vs. intravenous oxytocin in reducing blood loss after emergency cesarean delivery. *Int J Gynaecol Obstet*. 2006;95:2-7.
15. Vimala N, Mittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. *Int J Gynaecol Obstet*. 2006;92:106-10.

16. Brzozowska M, Lisiecki D, Kowalska-Koprek U, Karowicz-Bilińska A. [Comparison of carbetocin and oxytocin effectiveness for prevention of postpartum hemorrhage after caesarean delivery]. *Ginekol Pol.* 2015;86:107-12.
17. Moustafa A, Abd Elhady S, Shalaby H. Carbetocin versus Misoprostol in Reducing Blood Loss during Cesarean Section in low risk patients. A Randomized Controlled Trial. *EBWHJ.* 2020;10:209-15.
18. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. *Cochrane Database Syst Rev.* 2007;5:54-7.
19. Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. *Cochrane Database of Systematic Reviews.* 2012;4:123-8.
20. Gupta P, Sunita J, Shekhar C. Misoprostol versus Oxytocin in Prevention of Postpartum Hemorrhage. *J Androl Gynaecol.* 2016;4:4-10.
21. Adanikin A, Orji E, Adanikin P, Olaniyan O. Comparative study of rectal misoprostol to oxytocin infusion in preventing postpartum haemorrhage after caesarean section. *Nepal J Obstet Gynecol.* 2013;8:34-7.
22. Elbohoty AEH, Mohammed WE, Sweed M, Bahaa Eldin AM, Nabhan A, Abd-El-Maeboud KHI. Randomized controlled trial comparing carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following an elective cesarean delivery. *Int J Gynaecol Obstet.* 2016;134:324-8.
23. Fekih M, Jnifene A, Fathallah K, Ben Regaya L, Memmi A, Bouguizene S, et al. [Benefit of misoprostol for prevention of postpartum hemorrhage in cesarean section: a randomized controlled trial]. *J Gynecol Obstet Biol Reprod (Paris).* 2009;38:588-93.
24. el Sharkwy IAE. Carbetocin versus sublingual misoprostol plus oxytocin infusion for prevention of postpartum hemorrhage at cesarean section in patients with risk factors: a randomized, open trail study. *Arch Gynecol Obstet.* 2013;288:1231-6.

25. Ali A, Nasr A, Ahmed H, El-Rasheedy M, Badawy M. Carbetocin versus oxytocin and misoprostol in prevention of atonic post-partum hemorrhage in high risk patients planed for cesarean delivery. *Int J Reprod Contracept Obstet Gynecol.* 2018;7:10-4.

UNDER PEER REVIEW